Daptomycin for Injection

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, Todd C. Lee MD MPH FIDSA

Conditions

BacteremiaS. Aureus BacteremiaS. Aureus Bloodstream InfectionSkin Diseases, InfectiousSoft Tissue InfectionsStaphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia

Phase 2

Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)

CompletedNCT03643952

Merck Sharp & Dohme LLCBacteremia, Skin Diseases, Infectious, Soft Tissue Infections

Start: 2018-12-06End: 2020-04-07Updated: 2022-05-13

Phase 4

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

RecruitingNCT06637332

Todd C. Lee MD MPH FIDSAS. Aureus Bacteremia, S. Aureus Bloodstream Infection, Staphylococcus Aureus Bacteremia +2

Start: 2024-11-14End: 2029-11-01Target: 300Updated: 2026-09-09

Related Papers

Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci.

2021-12-158 citations